Valeant Pharmaceuticals (VRX) PT Lifted to $176 at Piper Jaffray; 'Neutral' Maintained

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. CRWD
6. ON
7. HNGE
8. INSP
9. SPY
10. MRVL

Go back to Valeant Pharmaceuticals (VRX) PT Lifted to $176 at Piper Jaffray; 'Neutral' Maintained

Valeant Pharma (VRX) to Acquire Salix Pharma (SLXP) in $14.5B Deal

February 22, 2015 4:29 PM EST

Valeant Pharma (NYSE: VRX) and Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Boards of Directors of both companies.

Salix Pharmaceuticals is a widely recognized gastrointestinal market leader with a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a strong near- term pipeline of... More